Currently, only the TNM staging is used to stage patients with colorectal cancer. Adjuvant treatment is based on this staging. Combining TNM staging with selected biomarkers might better define patients who are at risk for metastases

or recurrences and might define patients who would benefit from adjuvant treatment. In conclusion, our data showed that especially nuclear buy LEE011 localized CXCR4 determines prognosis for colorectal patients. The use of CXCR4 might improve the current staging of colorectal cancer patients. Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. References 1. Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 1:571–573CrossRef 2. Fuchs E (1882) Das Sarkom des Uvealtractus. Graefe’s Archiv für Ophthalmologie XII:233 3. Ruffini PA, Morandi P, Cabioglu N et al (2007) Manipulating the chemokine-chemokine

receptor network to treat cancer. Cancer 109:2392–2404CrossRefPubMed 4. Zlotnik A, Yoshie O, Nomiyama H (2006) The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 7:243CrossRefPubMed 5. Bacon K, Baggiolini M, Broxmeyer H et al (2002) Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 22:1067–1068CrossRefPubMed 6. Muller A, Homey B, Soto H et al (2001) Involvement of chemokine selleck chemicals llc receptors in breast cancer metastasis. Nature 410:50–56CrossRefPubMed Tamoxifen 7. Zeelenberg IS, Ruuls-Van Stalle L, Roos E (2003) The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 63:3833–3839PubMed 8. Koshiba T, Hosotani R, Miyamoto Y et al (2000) Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 6:3530–3535PubMed 9. Taichman RS, Cooper C, Keller ET et al (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis

to bone. Cancer Res 62:1832–1837PubMed 10. Kim J, Mori T, Chen SL et al (2006) Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 244:113–120CrossRefPubMed 11. Lapteva N, Yang AG, Sanders DE et al (2005) CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 12:84–89CrossRefPubMed 12. Liang Z, Yoon Y, Votaw J et al (2005) Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 65:967–971PubMed 13. Ottaiano A, Franco R, Aiello TA et al (2006) Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II–III colorectal cancer patients.